ViroMed Preps US Trial For First Diabetic Ulcer Gene Therapy
This article was originally published in PharmAsia News
After receiving US FDA approval to start a Phase III clinical trial with its gene therapy for diabetic peripheral neuropathy earlier this year, South Korea’s ViroMed is set for another Phase III study in the US, this time for a chronic non-healing ischemic diabetic foot ulcer therapy, which is the first gene therapy to be developed for this indication and which the firm is looking to partner.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.